No Data
TD Cowen Maintains GlaxoSmithKline(GSK.US) With Hold Rating, Maintains Target Price $45
GSK's Blood Cancer Drug Shows Improved Survival Compared To Johnson & Johnson's Darzalex
India Drug Delivery Devices Market 2024, With Profiles of Pfizer, Novartis, GlaxoSmithKline, India Medtronic, Cardinal Health, B. Braun Medical, Sun Pharmaceutical, 3M, Cipla & Bayer Zydus Pharma
GSK, Relation Therapeutics Partner to Advance Osteoarthritis, Fibrotic Disease Treatments
Glaxosmithkline (GSK.US) drugs reduce the risk of death by 42% in multiple myeloma studies.
Glaxosmithkline (GSK.US) reported that a study shows its drug belantamab mafodotin can reduce the risk of death for patients with multiple myeloma at first relapse or post-relapse by 42%.
Sector Update: Health Care Stocks Edge Higher Late Afternoon
